Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 25:15:825-836.
doi: 10.2147/IJWH.S379808. eCollection 2023.

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Tracy E Madsen  1   2 , Talia Sobel  3 , Seraphina Negash  2 , Tara Shrout Allen  4 , Marcia L Stefanick  5 , JoAnn E Manson  6 , Matthew Allison  7
Affiliations
Review

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Tracy E Madsen et al. Int J Womens Health. .

Abstract

Understanding the role of both menopausal hormone therapy (MHT) along with non-hormonal options for the treatment of vasomotor symptoms, sleep disruption, and genitourinary symptoms after menopause is critical to the health of women during middle and later life. Recent updates to the evidence for the treatment of menopausal symptoms pertaining to both hormonal and non-hormonal therapies as well as updated guidance from specialty societies can help guide clinicians in their treatment of women going through natural menopause or with estrogen deficiencies due to primary ovarian insufficiency or induced menopause from surgery or medications. The objective of this narrative review is to provide clinicians with an overview of MHT for the use of menopausal symptoms in women, incorporating updated primary evidence for risk versus benefit profiles, recent specialty society recommendations, and alternative, non-hormonal options. In this review, we summarize literature on the use of MHT for menopause-related symptomatology including options for formulations and dosages of MHT, non-hormonal treatment options, and the risk-benefit profile of MHT including long-term health consequences (eg, cardiovascular disease, cognitive decline, venous thromboembolism, and fracture risk). Finally, we highlight areas in which future research is needed to advance care of women after menopause. In summary, both hormonal (MHT) and non-hormonal options exist to treat symptoms of menopause. There is strong evidence for safety and effectiveness of MHT for the treatment of vasomotor symptoms among women who are less than 60 years of age, less than 10 years since menopause, and without significant cardiometabolic comorbidities. For others, treatment with hormonal versus non-hormonal therapies can be considered based on individual risk profiles, as well as other factors such as drug formulation, therapeutic goals, and symptom severity.

Keywords: cardiovascular disease; hormone therapy; menopause; stroke.

PubMed Disclaimer

Conflict of interest statement

Tracy Madsen reports grants from NIH NHLBI during the conduct of the study. The authors report no other conflicts of interest in this work.

References

    1. Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Women’s Heal. 2019;15:1–8. doi:10.1177/1745506519864009 - DOI - PMC - PubMed
    1. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: implications for Timing of Early Prevention: a Scientific Statement from the American Heart Association. Circulation. 2020;142(25):E506–E532. doi:10.1161/CIR.0000000000000912 - DOI - PubMed
    1. Faubion SS, Crandall CJ, Davis L, et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028 - DOI - PubMed
    1. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women - the women’s health initiative: a randomized trial. J Am Med Assoc. 2003;289(20):2673–2684. doi:10.1001/jama.289.20.2673 - DOI - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. J Am Med Assoc. 2002;288(321–323):262–266. doi:10.1093/med/9780190947088.003.0048 - DOI - PubMed